Responses
Clinical and epidemiological research
Extended report
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
Compose a Response to This Article
Other responses
No responses have been published for this article.